GLAUKOS
Glaukos Corporation is an ophthalmic medical technology company focused on the development and commercialization of breakthrough products and procedures designed to transform the treatment of glaucoma, one of the world’s leading causes of blindness. They have pioneered Micro-Invasive Glaucoma Surgery, or MIGS, in order to revolutionize the traditional glaucoma treatment and management paradigm. They launched the iStent®, their first MIGS device, in the United States in 2012. They are leverag... ing their platform technology to build a comprehensive and proprietary portfolio of injectable micro-scale therapies designed to address the complete range of glaucoma disease states and progression. They believe the iStent® is the smallest medical device ever approved by the Food and Drug Administration, or FDA, measuring 1.0 mm long and 0.33 mm wide. In June 2015, they completed an initial public offering and their shares are now traded on the New York Stock Exchange under the ticker symbol “GKOS”. The company was founded in 1998 and is based in San Clemente, California.
GLAUKOS
Industry:
Health Care Medical Wellness
Founded:
1998-01-01
Address:
San Clemente, California, United States
Country:
United States
Website Url:
http://www.glaukos.com
Total Employee:
251+
Status:
Active
Contact:
19493679984
Total Funding:
121 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible Google Font API LetsEncrypt Apple Mobile Web Clips Icon Google Tag Manager WordPress Content Delivery Network Wordpress Plugins Nginx
Similar Organizations
BetterNight
BetterNight is providing telehealth-based sleep solutions.
Big Health
Big Health is a digital therapeutics company operating a healthcare portal to offer behavioral programs for mental health issues.
CEL-SCI
CEL-SCI is a biotechnology company developing immunotherapy products for the treatment of cancer and other infectious diseases.
ComplexCare Solutions
ComplexCare Solutions is a health services company integrating care for complex, elderly, special needs, and dually-eligible individuals.
Minerva Surgical
Minerva Surgical is a medical device start-up company developing medical devices for women’s healthcare.
IVERIC bio
IVERIC bio is a biopharmaceutical company developing novel therapies for age-related macular degeneration.
UnitedHealth Group
UnitedHealth Group is a healthcare insurance company that offers health technology, health financial, and pharmacy services.
Current Advisors List
Board_member
2010-12-01
Board_member
2007-01-01
Board_member
Advisor
Board_member
Advisor
Advisor
Advisor
Current Employees Featured
Mory Gharib Co-Founder @ Glaukos
Co-Founder
Thomas W. Burns President & Chief Executive Officer @ Glaukos
President & Chief Executive Officer
2017-06-01
Richard A. Hill Co-Founder and Member of Scientific Advisory Board @ Glaukos
Co-Founder and Member of Scientific Advisory Board
Michele Allegretto Senior Vice President, Human Resources @ Glaukos
Senior Vice President, Human Resources
Craig Sherman Angel Investor @ Glaukos
Angel Investor
2010-12-01
Mark Rhein Head of Talent and Learning @ Glaukos
Head of Talent and Learning
2020-11-01
Chris M. Calcaterra Chief Operating Officer @ Glaukos
Chief Operating Officer
2017-02-01
Gabriella Szekely Vice President, Research and Development, Combination Pharmaceutical Products @ Glaukos
Vice President, Research and Development, Combination Pharmaceutical Products
Joseph E. Gilliam Chief Financial Officer @ Glaukos
Chief Financial Officer
2017-05-01
Olav Bergheim Co-founder @ Glaukos
Co-founder
Founder
Stock Details
Acquisitions List
Date | Company | Article | Price |
---|---|---|---|
2019-11-21 | Avedro | Avedro acquired by Glaukos | N/A |
2019-06-19 | DOSE Medical Corp. | DOSE Medical Corp. acquired by Glaukos | 2.5 M USD |
Investors List
Frazier Healthcare Partners
Frazier Healthcare Partners investment in Series F - Glaukos
Domain Associates
Domain Associates investment in Series F - Glaukos
Meritech Capital Partners
Meritech Capital Partners investment in Series F - Glaukos
OrbiMed
OrbiMed investment in Series F - Glaukos
InterWest Partners
InterWest Partners investment in Series F - Glaukos
Versant Ventures
Versant Ventures investment in Series F - Glaukos
Montreux Equity Partners
Montreux Equity Partners investment in Series F - Glaukos
OrbiMed
OrbiMed investment in Series E - Glaukos
Domain Associates
Domain Associates investment in Series E - Glaukos
Versant Ventures
Versant Ventures investment in Series E - Glaukos
Official Site Inspections
http://www.glaukos.com Semrush global rank: 1.91 M Semrush visits lastest month: 11.4 K
- Host name: 143.191.188.35.bc.googleusercontent.com
- IP address: 35.188.191.143
- Location: United States
- Latitude: 38.6583
- Longitude: -77.2481
- Timezone: America/New_York

More informations about "Glaukos"
Glaukos Charitable Foundation | About Us | Glaukos
The Glaukos Charitable Foundation is a philanthropic organization dedicated to helping the visually impaired and others in need. ... Glaukos has contributed more than 7,900 devices to underserved glaucoma patients in 56 different countries. …See details»
Advancing the Treatment of Ophthalmic Diseases
Glaukos is committed to investing in the future of ophthalmology to transform standards of care and improve patient lives. We’ve achieved many firsts in clinical studies and over the past several years, Glaukos has reinvested …See details»
Governance & Sustainability - Executive Management - Glaukos
Contact Us. Glaukos Corporation One Glaukos Way Aliso Viejo, CA 92656. 949-481-0510 Send Email Fax: 949-367-9984See details»
Glaukos - Investor Relations
Apr 9, 2025 Contact Us. Glaukos Corporation One Glaukos Way Aliso Viejo, CA 92656. 949-481-0510 Send Email Fax: 949-367-9984See details»
Glaukos - Crunchbase Company Profile & Funding
Glaukos Corporation is an ophthalmic medical technology company focused on the development and commercialization of breakthrough products and procedures designed to transform the treatment of glaucoma, one of the world’s leading …See details»
Glaukos - Leadership Team - The Org
The Leadership Team at Glaukos is responsible for steering the company's strategic vision and operational execution in the ophthalmic market. Comprising top executives from various …See details»
Governance & Sustainability - Board of Directors - Glaukos
Before joining Invitrogen, Mr. Hoffmeister spent 20 years with McKinsey & Company as a senior partner serving clients in the healthcare, private equity and chemical industries on issues of …See details»
Home - Glaukos Australia
Welcome to the Glaukos Australia & New Zealand website which has been created to share events and exhibition information specific to eye care professionals in Australia, New Zealand and Asia.. For more information about …See details»
Our History | About Us - Glaukos
Glaukos establishes a direct sales organization and launches iStent in the United States 2013 Glaukos secures 100% Medicare coverage for the iStent ® procedureSee details»
Glaukos Company Profile - Office Locations, Competitors ... - Craft
Oct 29, 2024 Glaukos has 5 employees across 16 locations and $383.48 m in annual revenue in FY 2024. See insights on Glaukos including office locations, competitors, revenue, financials, …See details»
Glaukos Corp Company Profile - GlobalData
Glaukos’ iStent is used in conjunction with cataract surgery. Glauko’s iStent improves outflow by creating a patent bypass between the anterior chamber and Schlemm’s canal. The company …See details»
Working at Glaukos Corporation - Great Place To Work®
Glaukos is a leading ophthalmic medical technology and pharmaceutical company formed in 1998. Our mission at Glaukos is to truly transform vision by pioneering novel, dropless …See details»
Glaukos Announces Executive Leadership Changes
Feb 7, 2022 Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal …See details»
Q&A With Glaukos CEO Thomas Burns - Glaucoma Today
In June 2015, Glaukos completed its initial public offering and began trading on the New York Stock Exchange under the ticker symbol GKOS. The milestone marked the culmination of 17 …See details»
Glaukos Corporation (GKOS) Q1 2025 Earnings Call Transcript
28 minutes ago Glaukos Corporation (NYSE:GKOS) Q1 2025 Earnings Conference Call April 30, 2025 4:30 PM ET. ... So we've been operating as an organization with a high degree of …See details»
Home | Glaukos
At Glaukos, our focus is to develop and lead the global ophthalmic market with novel therapies that advance the existing standard of care, and enrich the lives and treatment alternatives for …See details»
Earnings call transcript: Glaukos Corp beats Q1 2025 EPS forecast ...
1 day ago Glaukos Corporation (GKOS) reported a better-than-expected earnings per share (EPS) of -0.22 for the first quarter of 2025, surpassing the forecasted -0.35. Despite this …See details»
Glaukos Announces First Quarter 2025 Financial Results
6 hours ago Glaukos (www.glaukos.com) is an ophthalmic pharmaceutical and medical technology company focused on developing and commercializing novel therapies for the …See details»
Glaukos Announces the Release of its 2024 Sustainability Report
Apr 16, 2025 Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal …See details»
Glaukos projects 2025 sales in the $475M-$485M range
22 minutes ago Glaukos Corporation demonstrated robust Q1 2025 performance, driven by iDose TR adoption and progress in international markets. Management retained a positive …See details»